China stopped being a 'copycat' and started inventing new drugs not because of better science, but because they changed their insurance laws.
March 20, 2026
Original Paper
From Free Rider to Innovator: The Rise of China's Drug Development
SSRN · 6388198
The Takeaway
We usually assume innovation is sparked by funding scientists or building better labs. This study reveals that simply expanding the market size by adding drugs to the National Reimbursement List accounted for nearly double the innovation growth of talent flows and scientific knowledge combined.
From the abstract
This paper examines China's transition from pharmaceutical "free rider" to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study this transformation, we compile a comprehensive, synchronized database spanning the pharmaceutical drug development supply chain, covering scientific publications, clinical trials, drug development milestones for China, the U.S., a